

Datasheet for 600-401-Z51**BCMA Antibody****Overview**

Description:	Anti-BCMA (RABBIT) Antibody - 600-401-Z51
Item No.:	600-401-Z51
Size:	100 µg
Applications:	ELISA, IF, IHC, WB
Reactivity:	Human
Host Species:	Rabbit

Product Details

Background:	Members in the TNF superfamily regulate immune responses and induce apoptosis. Two novel members in the TNF family were recently identified and designated BAFF/BLyS/TALL-1/THANK/zTNF4 and April/TALL-2, respectively. BAFF was characterized as a B cell activator since it induced B cell proliferation and immunoglobulin secretion. April regulates immunological and non-immunological cell growth. Three receptors, BCMA (for B cell maturation protein), TACI, and BAFF-R, for BAFF were recently identified. BCMA, like TACI, binds BAFF and April. BAFF and its receptors induce B cell development and survival, activate NF-κB and c-jun N-terminal kinase, and are involved in B cell associated autoimmune diseases.
Synonyms:	BCMA Antibody, BCM, BCMA, CD269, TNFRSF13A, BCM, Tumor necrosis factor receptor superfamily member 17, B-cell maturation protein
Host Species:	Rabbit
Clonality:	Polyclonal
Format:	IgG

Target Details

Gene Name:	TNFRSF17
Reactivity:	Human
Immunogen Type:	Conjugated Peptide

Immunogen:	Anti-BCMA antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide mapping at the C-terminus of human BCMA. The immunogen is located within the last 50 amino acids of BCMA.
Purity/Specificity:	Anti-BCMA Antibody was affinity purified from monospecific antiserum by immunoaffinity chromatography. Cross reactivity with BCMA from other sources has not been determined.
Relevant Links:	• UniProtKB - Q02223 • GeneID - 608 • NCBI - NP_001183

Application Details

Tested Applications:	ELISA, IF, IHC, WB
Application Note:	Anti-BCMA Antibody has been tested for use in ELISA, Western Blotting, Immunohistochemistry-P and Immunofluorescence. Specific conditions for reactivity should be optimized by the end user. Expect a band at approximately 20 kDa in Western Blots of specific cell lysates and tissues. Positive controls: human spleen tissue lysate, human colon tissue lysate.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	1:50,000
IF:	10-20 µg/mL
IHC:	1-5 µg/mL
WB:	1-4 µg/mL

Formulation


Physical State:	Liquid (sterile filtered)
Concentration:	1.0mg/mL by UV absorbance at 280 nm
Buffer:	0.01 M Sodium Phosphate, 0.25 M Sodium Chloride, pH 7.2
Preservative:	0.02% (w/v) Sodium Azide
Stabilizer:	None

Shipping & Handling

Shipping Condition:	Wet Ice
----------------------------	---------

Storage Condition:	Antibody can be stored at 4°C up to one year. Antibodies should not be exposed to prolonged high temperatures. For extended storage, aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. Dilute only prior to immediate use.
Expiration:	Expiration date is one (1) year from date of receipt.

Images




Immunofluorescence Microscopy

Immunofluorescence Validation of BCMA.

Tissue: Human Spleen.

Fixation: 4% paraformaldehyde-fixed.

Primary: BCMA at 10 µg/mL, followed by goat anti-rabbit IgG secondary antibody at 1:500 dilution (red).



Immunohistochemistry

Immunohistochemistry Validation of BCMA.


Tissue: Human Spleen.

Fixation: paraffin-embedded, formaldehyde and blocked with 10% serum for 1 h at RT.

Antigen retrieval: heat mediation with a citrate buffer (pH6).

Primary Antibody: anti-BCMA antibody at 5 µg/ml overnight at 4°C.

Secondary: goat anti-rabbit IgG H&L (HRP) at 1:250. Counter stained with Hematoxylin.



Immunohistochemistry

Immunohistochemistry Validation of BCMA.


Tissue: Human Colon.

Fixation: paraffin-embedded, formaldehyde and blocked with 10% serum for 1 h at RT.

Antigen retrieval: heat mediation with a citrate buffer (pH6).

Primary Antibody: anti-BCMA antibody at 1 µg/ml overnight at 4°C.

Secondary: goat anti-rabbit IgG H&L (HRP) at 1:250. Counter stained with Hematoxylin.




Western Blot

Western Blot Validation of BCMA.

Load: 10 µg of human lysates. Lane 1: human spleen, Lane 2: human lymph node, Lane 3: human colon, Lane 4: human lung.


Primary Antibody: BCMA 2 µg/mL for 1 h incubation at RT in 5% NFDN/TBST.

Secondary: Goat Anti-Rabbit IgG HRP conjugate at 1:10000 dilution.



Immunohistochemistry

Immunohistochemistry of BCMA antibody. Tissue: Human spleen cells. Fixation: formalin fixed paraffin embedded. Antigen retrieval: not required. Primary antibody: BCMA antibody at 10 µg/mL for 1 h at RT. Secondary antibody: Peroxidase rabbit secondary antibody at 1:10,000 for 45 min at RT. Localization: BCMA is localized in the cell membrane and in the endomembrane system. Staining: BCMA as precipitated brown signal with hematoxylin blue nuclear counterstain.

**Western Blot**

Western Blot of BCMA antibody. Lane 1: Human spleen tissue lysate. Lane 2: K562 cell lysate. Lane 3: U937 cell lysate. Load: 35 µg per lane. Primary antibody: BCMA antibody at 5 µg/mL for overnight at 4°C. Secondary antibody: Peroxidase rabbit secondary antibody at 1:10,000 for 45 min at RT. Block: 5% BLOTTO overnight at 4°C. Predicted/Observed size: 20.2 kDa, 28 kDa for BCMA. Other band(s): BCMA splice variants and isoforms.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.